Eureka Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
32
About the Report
About the Report
Summary
Eureka Therapeutics Inc (Eureka Therapeutics) is a clinical stage biotechnology company which focuses on the development of novel T cell immunotherapies for the treatment of solid tumors. Its pipeline encompasses drug candidates for various indications such as liver cancer, hematological cancer, lung cancer, head and cervical cancers, prostate cancer, multiple mylenoma, ovarian and peritoneal cancer, among others. Eureka Therapeutics utilizes its proprietary science platform ARTEMIS, which enables the discovery of fully-human antibodies against intracellular antigens via the MHC-peptide complex. The company collaborated with Memorial Sloan-Kettering Cancer Center for the joint discovery and research of new antibodies. Eureka Therapeutics is headquartered in Emeryville, California, the US.
Eureka Therapeutics Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Eureka Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eureka Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Eureka Therapeutics Raises USD20 Million in Venture Financing 11
Eureka Therapeutics Raises USD60 Million in Series D Financing 12
Eureka Therapeutics Raises USD26.6 Million in Venture Financing 13
Eureka Therapeutics Raises USD21 Million in Series C Venture Financing 14
Partnerships 15
Zhongyuan Union Cell & Gene Engineering to Form Joint Venture with Tibet Based Biotechnology Firm and Eureka Therapeutics 15
Janssen Biotech Enters into Agreement with Eureka Therapeutics 16
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 17
Licensing Agreements 18
Boehringer Ingelheim Exercises Option for Licensing Agreement with Eureka Therapeutics 18
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 19
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 20
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 21
Eureka Therapeutics Inc-Key Competitors 23
Eureka Therapeutics Inc-Key Employees 24
Eureka Therapeutics Inc-Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Corporate Communications 26
Jul 16, 2018: Eureka Therapeutics Announces New Scientific Advisory Board Members 26
Apr 20, 2017: Eureka Therapeutics Expands Scientific Advisory Board with Appointment of Industry Leaders Dr. Hideho Okada and Dr. Nai-Kong Cheung 27
Product News 28
08/30/2018: Eureka Therapeutics to Present Proof-of-Concept Preliminary Data from Ongoing China Clinical Study of ET140202 at CAR-TCR 2018 Summit 28
Aug 16, 2018: Eureka Therapeutics announces publication of armored t-cell proof-of-concept study in nature biotechnology 29
Clinical Trials 30
Nov 27, 2017: Eureka Announces FDA Allowance of Investigational New Drug Application for ET190L1-ARTEMIS T cell Therapy in Relapsed and Refractory CD19+ Non-Hodgkin Lymphoma 30
Jun 07, 2017: Eureka Therapeutics and City of Hope Announce Agreement to Conduct Phase 1 Clinical Trial of Investigational ET1402L1 CAR-T Therapy in Liver Cancer 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List of Figure
List of Figures
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eureka Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eureka Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Eureka Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9
Eureka Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eureka Therapeutics Raises USD20 Million in Venture Financing 11
Eureka Therapeutics Raises USD60 Million in Series D Financing 12
Eureka Therapeutics Raises USD26.6 Million in Venture Financing 13
Eureka Therapeutics Raises USD21 Million in Series C Venture Financing 14
Zhongyuan Union Cell & Gene Engineering to Form Joint Venture with Tibet Based Biotechnology Firm and Eureka Therapeutics 15
Janssen Biotech Enters into Agreement with Eureka Therapeutics 16
Boehringer Ingelheim Enters into Research Agreement with Eureka Therapeutics 17
Boehringer Ingelheim Exercises Option for Licensing Agreement with Eureka Therapeutics 18
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 19
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 20
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 21
Eureka Therapeutics Inc, Key Competitors 23
Eureka Therapeutics Inc, Key Employees 24
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.